Steve Rowe, M.D., professor of medicine at the University of Alabama at Birmingham and director of the Gregory Fleming James Cystic Fibrosis Research Center, is available to discuss the FDA approval of Trikafta, a new triple combination therapy for CF.  Rowe has been leading clinical trials of the combination therapies that make up Trikafta in conjunction with Vertex Pharmaceuticals.  Rowe calls this a historic moment for CF patients, as the new drug should provide lung function improvement for 90 percent of all people with CF.

UAB's studio is available for live or taped interviews: